Nos
0
essais cliniques ouverts
Vous êtes patient : votre médecin est à votre disposition pour vous expliquer si votre pathologie vous rend eligible à un essai.
Qu’est ce qu’un essai clinique ?
Vous êtes médecin : Vous avez un patient éligible à l’un de ces essais ? Nous vous invitons à joindre le contact indiqué pour chaque essai.
Date de mise à jour : Septembre 2021
PAR
LOCALISATION
TUMORALE
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03968419 | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) | 2 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | Stade IB-IIIA | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03447769 | Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer (Canopy-A) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | IIA-IIIA and IIIB (atteintes résiduelles N2 seulement) | 2 | marie.wislez@aphp.fr | Cochin |
| NCT03924869 | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | I or IIA | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03977194 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | metastatic | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE) | 3 | Cancer du poumon non à petites cellules (NSCLC) | PDL1 (expression >50%) | Critères | Stage IV or . Unresectable and non-eligible to radiotherapy stage III | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) | 3 | Cancer du poumon non à petites cellules (NSCLC) | Without known alteration | Critères | Advanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) | 2 | marie.wislez@aphp.fr | Cochin |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) | 3 | Cancer du poumon non à petites cellules (NSCLC) | Ret-fusion | Critères | Advanced or metastatic : Stage IIIB-IIIC or Stage IV | 1 | marie.wislez@aphp.fr / elizabeth.fabre@aphp.fr | Cochin/HEGP |
| NCT04323436 | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | 2 | Cancer du poumon non à petites cellules (NSCLC) | METΔex14 mutation | Critères | locally advanced or metastatic | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04233021 | Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) | 2 | Cancer du poumon non à petites cellules (NSCLC) | EGFR | Critères | metastatic (Leptomeningeal & Brain) | 2, 3 or 4 | marie.wislez@aphp.fr | Cochin |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | 2 | Cancer du poumon non à petites cellules (NSCLC) | MET Amplified, EGFR | Critères | Locally advanced or metastatic | 2 | marie.wislez@aphp.fr | Cochin |
| NCT04111705 | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) | 2 | Cancer du poumon non à petites cellules (NSCLC) | ALK rearrangement | Critères | locally advanced or metastatic (Stage IIIB or IV ) | 2 | marie.wislez@aphp.fr | Cochin |
| NCT03351361 | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | Stage IV or non-treatable by radiotherapy or surgery stage III | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) | 3 | Cancer du poumon à petites cellules (SCLC) | – | Critères | locally (Limited-Stage SCLC (Stage I-III) | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03976375 | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | metastatic (Stage IV: M1a, M1b, M1c) | 2 | jacques.medioni@aphp.fr | HEGP |
| NCT04154956 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) | 3 | Cancer du poumon non à petites cellules (NSCLC) | CEACAM5 positive | Critères | metastatic | 2 | jacques.medioni@aphp.fr | HEGP |
| NCT04526782 | ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) | 2 | Cancer du poumon non à petites cellules (NSCLC) | BRAF | Critères | Stage IV | 2 | marie.wislez@aphp.fr | Cochin |
| NCT03833154 | Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4) | 3 | Carcinoma, Non-Small-Cell Lung | – | Critères | Stage I to II NSCLC | – | elizabeth.fabre@aphp.fr | HEGP |
| NCT03178552 | A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST | 2,3 | Non-Small Cell Lung Cancer | – | Critères | Unresectable stage IIIB or IV | >1 | felizabeth.fabre@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04006262 | Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma | 2 | Adénocaecinome oeso-gastrique | dMMR et/ou MSI | Critères | Péri-op | Péri-op | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03006432 | Phase III randomised trial to evaluate FOLFOX with or without docetaxel (TFOX) as 1st line chemotherapy for locally advanced or metastatic oesophago-gastric carcinoma | 3 | Adénocaecinome oeso-gastrique | HER-2 négative | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT03959293 | Clinical Trial Evaluating FOLFIRI + Durvalumab vs FOLFIRI + Durvalumab and Tremelimumab in Second-line Treatment of Patients With Advanced Gastric or Gastro-oesophageal Junction Adenocarcinoma | 2 | Adénocaecinome oeso-gastrique | – | Critères | Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03760822 | Second-Line Chemotherapy With Ramucirumab +/- Paclitaxel in Elderly Advanced Gastric or Gastroesophageal Junction Cancer Patients | 2 | Adénocaecinome oeso-gastrique | – | Critères | Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT03722108 | Regorafenib Combined With Irinotecan as Second-line in Patients With Metastatic Gastro-oesophageal Adenocarcinomas | 2 | Adénocaecinome oeso-gastrique | – | Critères | Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT04543617 | A Study of Atezolizumab With or Without Tiragolumab in Participants With Unresectable Esophageal Squamous Cell Carcinoma Whose Cancers Have Not Progressed Following Definitive Concurrent Chemoradiotherapy | 3 | Carcinome Epidermoïde de l’oesophage | – | Critères | LA | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03748134 | Sintilimab or Placebo With Chemotherapy in Esophageal Squamous Cell Carcinoma | 3 | Carcinome Epidermoïde de l’oesophage | – | Critères | LA-Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03719924 | Nal-iri/lv5-fu Versus Paclitaxel as Second Line Therapy in Patients With Metastatic Oesophageal Squamous Cell Carcinoma | 3 | Carcinome Epidermoïde de l’oesophage | – | Critères | Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03783442 | A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma | 3 | Esophageal Squamous Cell Carcinoma (ESCC) | – | Critères | Unresectable, locally advanced recurrent or metastatic | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02502370 | Phase III Trial Investigating the Potential Benefit of Adjvant Chemotherapy for Small Bowel Adenocarcinoma | 3 | INTESTIN GRELE | – | Critères | Adjuvant | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04163887 | Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases (METALAP) | Non Applicable / Chirurgie | Métastase hépatique de cancer du colon | – | Critères | Metastatique | – | david.fuks@aphp.fr | Cochin |
| NCT04120701 | Circulating tumor dna based decision for adjuvant treatment in colon cancer stage II | 3 | Cancer du colon | – | Critères | Stage II-III | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT02945033 | Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (ASPIK French) | 3 | Cancer du colon | PI3K | Critères | Stage II-III | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT02967289 | A Phase III, Randomised, international trial comparing mFOLFIRINOX triplet chemotherapy to mFOLFOX for high- risk stage III colon cancer in adjuvant setting | 3 | Cancer du colon | – | Critères | Stage III | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT02355379 | Randomised phase III trial evaluating adjuvant chemotherapy after the stage III colon adenocarcinoma resection for patient of 70 year old or more | 3 | Cancer du colon | – | Critères | Stage III | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT02885753 | Systemic Oxaliplatin or Intra-arterial Chemotherapy Combined With LV5FU2 and an Target Therapy in First Line Treatment of Metastatic Colorectal Cancer Restricted to the Liver (OSCAR) | 3 | Cancer du colon | – | Critères | Métastases hépatiques | 1 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT03164655 | A randomized phase II study comparing treatment intensification with hepatic arterial infusion chemotherapy plus systemic chemotherapy to systemic chemotherapy alone in patients with liver-only colorectal metastases considered still non resectable after at least two months of systemic induction chemotherapy: SULTAN (improving SUrgery of Liver metastases: a Trial of the Arterial chemotherapy Network) | 2 | Cancer du colon | – | Critères | Métastases hépatiques | 2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT04456699 | A Phase 3 Randomized, Open-label Study to Evaluate the Efficacy and Safety of Olaparib Alone or in Combination With Bevacizumab Compared to Bevacizumab with 5-FU in Participants with Unresectable or Metastatic Colorectal Cancer who Have Not Progressed Following First-line Induction of FOLFOX With Bevacizumab (LYNK-003) | 3 | Cancer du colon | – | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03584711 | A Phase II Study Evaluating FOLFOX + Panitumumab According to a « Stop and go » Strategy With a Reintroduction Loop After Progression on Fluoropyrimidine as Maintenance Treatment, as the First Line in Patients With Metastatic Colorectal Adenocarcinoma Without a RAS Mutation | 2 | Cancer du colon | RAS wt; BRAF wt | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT04034459 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | 2 | Cancer du colon | BRAF muté (V600E). RAS wt | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03186326 | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) | 2 | Cancer du colon | MSI | Critères | Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT04392479 | TWICE-IRI: Optimization of second-line therapy with aflibercept, irinotecan (day 1 or day 1,3), 5-Fluorouracile and folinic acid in patients with metastatic colorectal cancer. A randomized Phase III study. | 3 | Cancer du colon | – | Critères | Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT03829462 | A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1 | 3 | Cancer du colon | génotype A/A (rs9344) de la cycline D1 | Critères | Métastatique | ≥2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT04737187 | Phase III study of trifluridine/tipiracil in combination with bevacizumab vs trifluridine/tipiracil single agent in patients with refractory metastatic colorectal cancer | 3 | Cancer du colon | – | Critères | Métastatique | 2,3 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT04450836 | Sequences Of REGorafenib And Trifluridine/Tipiracil in Patients With Metastatic Colorectal Cancer (SOREGATT) | 2 | Cancer du colon | – | Critères | Métastatique | ≥2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03875781 | Non inferiority multicenter phase III randomized trial comparing preoperative chemotherapy only to chemotherapy followed by chemoradiotherapy for locally advanced resectable rectal cancer | 2 | Cancer du Rectum | – | Critères | Pré-opératoire | Pré-op | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04791735 | Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma (LapCHC) | Non Applicable / Chirurgie | Hepatocellular carcinoma | – | Critères | Solitary or multifocal resectable | – | david.fuks@aphp.fr | Cochin |
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | 3 | Cholangiocarcinome | Réarrangement FGFR2 | Critères | LA-Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03364530 | Hepatic Arterial Infusion of Gemcitabine-oxaliplatin for Second-line Therapy in Non-metastatic Unresectable Intra-hepatic Cholangiocarcinoma | 2 | Intra-hepatic Cholangiocarcinoma (GEMOXIA-02) | – | Critères | Non résecable-Non Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) | 2 | Cholangiocarcinoma | FGFR2 | Critères | >ou= 2 | romain.coriat@aphp.fr | Cochin | |
| NCT04163900 | Comparing NUC-1031 Plus Cisplatin to Gemcitabine Plus Cisplatin in Patients With Advanced Biliary Tract Cancer | 3 | Biliary Tract Cancer | – | Critères | locally advanced, unresectable or metastatic | 1 ou 2 | romain.coriat@aphp.fr | Cochin |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | 3 | Cholangiocarcinoma | FGFR2 fusions/translocations | Critères | unresectable locally advanced or metastatic | 1 | romain.coriat@aphp.fr | Cochin |
| NCT03630640 | Neoadjuvant and Adjuvant Nivolumab in HCC Patients Treated by Electroporation (NIVOLEP) | 2 | Hepatocellular Carcinoma | – | Critères | 2 | stanislas.pol@aphp.fr | Cochin | |
| NCT04163887 | Effect of the Laparoscopic Approach in Reducing Postoperative Severe Complications Following Hepatectomy for Colorectal Liver Metastases (METALAP) | Non Applicable / Chirurgie | Métastase hépatique de cancer du colon | – | Critères | Metastatique | – | david.fuks@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03679169 | Evaluation of Complete microscopicE Resection Margin (R0) and Lymph Node Involvement After Standard Pancreatosplenectomy (SPS) Versus Radical Anterograde Modular Pancreatosplenectomy (REMIND-01) | Non Applicable / Chirurgie | Cancer du pancréas | – | Critères | Invasive resectable | – | david.fuks@aphp.fr | Cochin |
| NCT03693677 | First Line Metastatic Pancreatic Cancer : 5FU/LV+Nal-IRI, Gemcitabine+Nab-paclitaxel or a Sequential Regimen of 2 Months 5FU/LV+Nal-IRI | 2 | Adénocaecinome du Pancreas | – | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT04348045 | Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02) | 2 | Adénocaecinome du Pancreas | BRCA / KRAS | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT04167007 | FOLFOX vs Gemcitabine in Patients With Metastatic Pancreatic Cancer Non-fit to FOLFIRINOX | 3 | Adénocaecinome du Pancreas | – | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT04083235 | A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3)A Study to Assess the Effectiveness and Safety of Irinotecan Liposome Injection, 5-fluorouracil/Leucovorin Plus Oxaliplatin in Patients Not Previously Treated for Metastatic Pancreatic Cancer, Compared to Nab-paclitaxel+Gemcitabine Treatment (NAPOLI 3) | 3 | Adenocarcinoma of the Pancreas | – | Critères | metastatic | 1 | romain.coriat@aphp.fr | Cochin |
| NCT02959879 | Neo-adjuvant FOLF(IRIN)OX for Resectable Pancreatic Adenocarcinoma (PANACHE01) | 2 | Pancreatic Duct Adenocarcinoma | – | Critères | Resectable adenocarcinoma | neoadjuvant | romain.coriat@aphp.fr | Cochin |
| NCT02676349 | Neoadjuvant mFolfirinox With or Without Preoperative Concomitant Chemoradiotherapy in Patients With Borderline Resectable Pancreatic Carcinoma (PANDAS-PRODIGE 44) | 2 | Pancreatic Carcinoma | – | Critères | Borderline resectable status | neoadjuvant | romain.coriat@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03351296 | Randomized phase 2 trial of two chemotherapy regimens plus or minus bevacizumab in patients with well differentiated pancreatic neuroendocrine tumors | 2 | tumeur neuroendocrine du pancréas | – | Critères | LA-Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT02820857 | Assessment of the Efficacy of Bevacizumab in Combination With Folfiri as Second-line Treatment in Patients Suffering From an Advanced Inoperable Poorly Differentiated Neuroendocrine Carcinoma of an Unknown or Gastroentero-pancreatic Primary Cancer | 2 | tumeur neuroendocrine | – | Critères | LA-Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03591731 | A GCO trial exploring the efficacy and safety of Nivolumab monotherapy or Nivolumab plus Ipilimumab in pre-treated patients with advanced, refractory pulmonary or gastroenteropancreatic poorly differentiated neuroendocrine tumors (NECs) | 2 | tumeur neuroendocrine | – | Critères | LA-Métastatique | 2,3 | Julien Taieb : jtaieb75@gmail.com / romain.coriat@aphp.fr / Elizabeth.fabre@aphp.fr | HEGP/Cochin |
| NCT04268121 | Efficacy of Neoadjuvant Chemotherapy in Terms of DFS in Patients With Localized Digestive Neuroendocrine Carcinomas (NEONEC) | 2 | Neuroendocrine Carcinoma in gastro | – | Critères | localized | neoadjuvant | romain.coriat@aphp.fr | Cochin |
| NCT04325425 | Chemotherapy For Metastatic Grade 3 Poorly Differentiated NEuroendocrine Carcinoma Of GastroEnteroPancreatic And Unknown Primary (FOLFIRINEC) | 2 | Neuroendocrine Carcinoma in gastro | – | Critères | Grade 3 or high grade MiNEN | 1 | romain.coriat@aphp.fr | Cochin |
| NCT02260505 | A randomized, multicentre, Phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumours (GIST) | 3 | GIST | KIT positivity | Critères | Adjuvant | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03598270 | Platinum-based Chemotherapy With Atezolizumab and Niraparib in Patients With Recurrent Ovarian Cancer (ANITA) | 3 | Ovarian Carcinoma | – | Critères | high- grade serous or endometrioid ovarian, primary peritoneal or tubal carcinoma | 1,2,3 | bruno.borghese@aphp.fr / anne-sophie.bats@aphp.fr | Cochin/HEGP |
| NCT03249142 | Immunotherapy With Neo-adjuvant Chemotherapy for OVarian Cancer (INeOV) | 1,2 | ovarian cancer,fallopian tube | – | Critères | newly diagnosed | 1 | jerome.alexandre@aphp.fr | Cochin |
| NCT03752216 | NIraparib and Quality Of LifE is a Longitudinal Study Evaluating in Real Life the Tolerability of Niraparib. (NiQoLe) | 4 | Ovarian Cancer | – | Critères | high grade epithelial ovarian cancer | 2 | jerome.alexandre@aphp.fr | Cochin |
| NCT04209855 | A Study of Mirvetuximab Soravtansine vs. Investigator’s Choice of Chemotherapy in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression (MIRASOL) | 3 | Epithelial Ovarian Cancer Peritoneal Cancer Fallopian Tube Cancer | – | Critères | high-grade | 2 | bruno.borghese@aphp.fr | Cochin |
| NCT02866370 | Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC) | 2 | Ovarian Clear Cell Carcinoma Endometrial Clear Cell Carcinoma | – | Critères | Progressive or recurrent | >ou= 2 | bruno.borghese@aphp.fr | Cochin |
| NCT03842982 | Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Ovarian Cancer (CHIPPI) | 3 | Ovarian Cancer | – | Critères | Stage III | 2 | anne-sophie.bats@aphp.fr | HEGP |
| NCT03737643 | Durvalumab Treatment in Combination With Chemotherapy and Bevacizumab, Followed by Maintenance Durvalumab, Bevacizumab and Olaparib Treatment in Advanced Ovarian Cancer Patients. | 3 | Advanced Ovarian Cancer | – | Critères | advanced (Stage III-IV) | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04246489 | Bintrafusp Alfa Monotherapy in Platinum-Experienced Cervical Cancer | 2 | Uterine Cervical Neoplasms | – | Critères | advanced unresectable and/or metastatic | 1,2 | bruno.borghese@aphp.fr | Cochin |
| NCT03556839 | Platinum Chemotherapy Plus Paclitaxel With Bevacizumab and Atezolizumab in Metastatic Carcinoma of the Cervix (BEATcc) | 3 | Carcinoma of the Cervix | – | Critères | metastatic (stage IVB), persistent, or recurrent | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03517449 | Lenvatinib in Combination With Pembrolizumab Versus Treatment of Physician’s Choice in Participants With Advanced Endometrial Cancer (MK-3475-775/E7080-G000-309 Per Merck Standard Convention [KEYNOTE-775]) | 3 | Endometrial Neoplasms | – | Critères | advanced, recurrent or metastatic | 2 | jerome.alexandre@aphp.fr | Cochin |
| NCT04634877 | Study of Pembrolizumab (MK-3475) in Combination With Adjuvant Chemotherapy With or Without Radiotherapy in Participants With Newly Diagnosed Endometrial Cancer After Surgery With Curative Intent | 3 | Endometrial Neoplasms | – | Critères | newly diagnosed | 1 | jerome.alexandre@aphp.fr | Cochin |
| NCT02866370 | Study Of Nintedanib Compared To Chemotherapy in Patients With Recurrent Clear Cell Carcinoma Of The Ovary Or Endometrium (NiCCC) | 2 | Ovarian Clear Cell Carcinoma Endometrial Clear Cell Carcinoma | – | Critères | Progressive or recurrent | >ou= 2 | bruno.borghese@aphp.fr | Cochin |
| NCT04463771 | Safety and Efficacy of Retifanlimab (INCMGA00012) Alone or in Combination With Other Therapies in Participants With Advanced or Metastatic Endometrial Cancer Who Have Progressed on or After Platinum-based Chemotherapy. | 2 | Endometrial Cancer | – | Critères | Advanced or Metastatic | 2 | jerome.alexandre@aphp.fr | Cochin |
| NCT03745950 | UTOLA: UTerin OLAparib (UTOLA | 2 | Endometrial Cancer | MSI-High, MMR, POLE, FGFR mutations/alterations | Critères | advanced/metastatic | 2 | jerome.alexandre@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03968419 | This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N) | 2 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | Stade IB-IIIA | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03447769 | Study of Efficacy and Safety of Canakinumab as Adjuvant Therapy in Adult Subjects With Stages AJCC/UICC v. 8 II-IIIA and IIIB (T>5cm N2) Completely Resected Non-small Cell Lung Cancer (Canopy-A) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | IIA-IIIA and IIIB (atteintes résiduelles N2 seulement) | 2 | marie.wislez@aphp.fr | Cochin |
| NCT03924869 | Efficacy and Safety Study of Stereotactic Body Radiotherapy (SBRT) With or Without Pembrolizumab (MK-3475) in Adults With Unresected Stage I or IIA Non-Small Cell Lung Cancer (NSCLC) (MK-3475-867/KEYNOTE-867) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | I or IIA | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04026412 | A Study of Nivolumab and Ipilimumab in Untreated Patients With Stage 3 Non-small Cell Lung Cancer (NSCLC) That is Unable or Not Planned to be Removed by Surgery (CheckMate73L) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | Locally advanced stage IIIA, IIIB, or IIIC (T1-2 N2-3 M0, T3 N1-3 M0, or T4 N0-3 M0) | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03977194 | Atezolizumab in Elderly Patients With Advanced Non-Small-Cell Lung Cancer and Receiving Carboplatin Paclitaxel Chemotherapy (ELDERLY) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | metastatic | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE) | 3 | Cancer du poumon non à petites cellules (NSCLC) | PDL1 (expression >50%) | Critères | Stage IV or . Unresectable and non-eligible to radiotherapy stage III | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04475939 | Placebo-controlled Study Comparing Niraparib Plus Pembrolizumab Versus Placebo and Pembrolizumab as Maintenance Therapy (ZEAL-1L) | 3 | Cancer du poumon non à petites cellules (NSCLC) | Without known alteration | Critères | Advanced (Stage IIIB not amenable to definitive chemoradiotherapy) or metastatic (Stage IV) | 2 | marie.wislez@aphp.fr | Cochin |
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) | 3 | Cancer du poumon non à petites cellules (NSCLC) | Ret-fusion | Critères | Advanced or metastatic : Stage IIIB-IIIC or Stage IV | 1 | marie.wislez@aphp.fr / francoise.lepimpec-barthes@aphp.fr | Cochin/HEGP |
| NCT04323436 | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | 2 | Cancer du poumon non à petites cellules (NSCLC) | METΔex14 mutation | Critères | locally advanced or metastatic | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04233021 | Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) | 2 | Cancer du poumon non à petites cellules (NSCLC) | EGFR | Critères | metastatic (Leptomeningeal & Brain) | 2, 3 or 4 | marie.wislez@aphp.fr | Cochin |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | 2 | Cancer du poumon non à petites cellules (NSCLC) | MET Amplified, EGFR | Critères | Locally advanced or metastatic | 2 | marie.wislez@aphp.fr | Cochin |
| NCT04111705 | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) | 2 | Cancer du poumon non à petites cellules (NSCLC) | ALK rearrangement | Critères | locally advanced or metastatic (Stage IIIB or IV ) | 2 | marie.wislez@aphp.fr | Cochin |
| NCT03351361 | Nivolumab and Ipilimumab Versus Chimiotherapy in First Line Treatment in PS 2 or Elderly in Advanced NSCLC Patients (eNERGY) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | Stage IV or non-treatable by radiotherapy or surgery stage III | 1 | marie.wislez@aphp.fr | Cochin |
| NCT04624204 | Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) | 3 | Cancer du poumon à petites cellules (SCLC) | – | Critères | locally (Limited-Stage SCLC (Stage I-III) | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03976375 | Efficacy and Safety of Pembrolizumab (MK-3475) With Lenvatinib (E7080/MK-7902) vs. Docetaxel in Participants With Metastatic Non-Small Cell Lung Cancer (NSCLC) and Progressive Disease (PD) After Platinum Doublet Chemotherapy and Immunotherapy (MK-7902-008/E7080-G000-316/LEAP-008) | 3 | Cancer du poumon non à petites cellules (NSCLC) | – | Critères | metastatic (Stage IV: M1a, M1b, M1c) | 2 | jacques.medioni@aphp.fr | HEGP |
| NCT04154956 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) | 3 | Cancer du poumon non à petites cellules (NSCLC) | CEACAM5 positive | Critères | metastatic | 2 | jacques.medioni@aphp.fr | HEGP |
| NCT04526782 | ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) | 2 | Cancer du poumon non à petites cellules (NSCLC) | BRAF | Critères | Stage IV | 2 | marie.wislez@aphp.fr | Cochin |
| NCT03833154 | Durvalumab vs Placebo With Stereotactic Body Radiation Therapy in Early Stage Unresected Non-small Cell Lung Cancer Patients (PACIFIC-4) | 3 | Carcinoma, Non-Small-Cell Lung | – | Critères | Stage I to II NSCLC | – | francoise.lepimpec-barthes@aphp.fr | HEGP |
| NCT03178552 | A Study to Evaluate Efficacy and Safety of Multiple Targeted Therapies as Treatments for Participants With Non-Small Cell Lung Cancer (NSCLC) (B-FAST | 2,3 | Non-Small Cell Lung Cancer | – | Critères | Unresectable stage IIIB or IV | >1 | francoise.lepimpec-barthes@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03549715 | NEoadjuvant Dose-dense MVAC In cOmbination With Durvalumab and Tremelimumab in Muscle-invasive Urothelial Carcinoma (NEMIO) | 1,2 | Infiltrating Bladder Urothelial Carcinoma | – | Critères | invasive | Adjuvant | jacques.medioni@aphp.fr / michael.peyromaure@aphp.fr | HEGP/Cochin |
| NCT04209114 | A Study of Nivolumab Plus Bempegaldesleukin (Bempeg/NKTR-214) vs Nivolumab Alone vs Standard of Care in Participants With Bladder Cancer That Has Invaded the Muscle Wall of the Bladder and Who Cannot Get Cisplatin, a Type of Medicine Given to Treat Bladder Cancer | 3 | Bladder cancer | – | Critères | muscle-invasive | pré/post-op | jacques.medioni@aphp.fr | HEGP |
| NCT03799835 | Atezolizumab Plus One-year BCG Bladder Instillation in BCG-naive High-risk Non-muscle Invasive Bladder Cancer Patients (ALBAN) | 3 | Bladder Cancer | – | Critères | T1 tumor and/or High grade (WHO 2004) and/or Grade 3 (WHO1973) and/or Carcinoma in situ | 1,2 | michael.peyromaure@aphp.fr / stephane.oudard@aphp.fr | Cochin/HEGP |
| NCT04149574 | A Study Comparing the Efficacy and Safety of Nivolumab in Combination With Bacillus Calmette-Guerin (BCG) Versus BCG Alone in Participants With High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (CheckMate 7G8) | 3 | Bladder Cancer | – | Critères | Persistent or recurrent disease | >ou= 2 | michael.peyromaure@aphp.fr | Cochin |
| NCT03924895 | Perioperative Pembrolizumab (MK-3475) Plus Cystectomy or Perioperative Pembrolizumab Plus Enfortumab Vedotin Plus Cystectomy Versus Cystectomy Alone in Cisplatin-ineligible Participants With Muscle-invasive Bladder Cancer | 3 | Bladder cancer | – | Critères | Péri-op | michael.peyromaure@aphp.fr / stephane.oudard@aphp.fr | Cochin/HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | 2 | Carcinome épidermoïde cutané avancé | – | Critères | locally advanced or metastatic | 1,2 | selim.aractingi@aphp.fr | Cochin |
| NCT03469804 | Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma (KAPKEY) | 2 | Kaposi Sarcoma | – | Critères | Progressive disease | >ou= 2 | selim.aractingi@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03809988 | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA) | 2 | breast cancer | ER + or/and PgR + & HER2 – | Critères | Advanced | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT03659136 | The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | 2 | breast cancer | ER + or/and PgR + & HER2 – | Critères | Locally advanced or metastatic | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT03701334 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) | 3 | Breast cancer | ER + or/and PgR + & HER2 – | Critères | early invasive | 1 | jacques.medioni@aphp.fr | HEGP |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer | 2,3 | Breast Cancer | ER + and HER2 – | Critères | loco-regional recurrent or metastatic | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) | 3 | Breast cancer | ER + and HER2 – | Critères | Localized invasive | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03809988 | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA) | 2 | breast cancer | ER + or/and PgR + & HER2 – | Critères | Advanced | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT03659136 | The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | 2 | breast cancer | ER + or/and PgR + & HER2 – | Critères | Locally advanced or metastatic | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT03701334 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) | 3 | Breast cancer | ER + or/and PgR + & HER2 – | Critères | early invasive | 1 | jacques.medioni@aphp.fr | HEGP |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer | 2,3 | Breast Cancer | ER + and HER2 – | Critères | loco-regional recurrent or metastatic | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) | 3 | Breast cancer | ER + and HER2 – | Critères | Localized invasive | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02313389 | Maintenance Treatment Versus Observation in Elderly Patients With PCNS Lymphoma (BLOCAGE-01) | 3 | Primary Central Nervous System Lymphoma | – | Critères | newly diagnosed | 1 | didier.bouscary@aphp.fr | Cochin |
| NCT02416388 | Study to Improve OS in 18 to 60 Year-old Patients, Comparing Daunorubicin Versus High Dose Idarubicin Induction Regimens, High Dose Versus Intermediate Dose Cytarabine Consolidation Regimens, and Standard Versus MMF Prophylaxis of GvHD in Allografted Patients in First CR (BIG-1) | 2,3 | Acute Myeloid Leukemia (AML) | – | Critères | newly diagnosed de novo or secondary type AML | 1 | didier.bouscary@aphp.fr | Cochin |
| NCT02619630 | Multicenter Study of Risk-adapted Treatment for T-lineage ALL of Young Adults (18-59 Years Old) (GRAALL-2014/T) | 2 | T-cell Adult Acute Lymphoblastic Leukemia | – | Critères | 1 | didier.bouscary@aphp.fr | Cochin | |
| NCT03993912 | Compare Lenalidomide and Subcutaneous Daratumumab vs Lenalidomide and Dexamethasone in Frail Subjects With Previously Untreated Multiple Myeloma Who Are Ineligible for High Dose Therapy (IFM2017_03) | 3 | Multiple Myeloma | – | Critères | 1 | didier.bouscary@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02760498 | Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma | 2 | Carcinome épidermoïde cutané avancé | – | Critères | locally advanced or metastatic | 1,2 | selim.aractingi@aphp.fr | Cochin |
| NCT03469804 | Phase II Multicentric Study of Pembrolizumab in Classic or Endemic Kaposi’s Sarcoma (KAPKEY) | 2 | Kaposi Sarcoma | – | Critères | Progressive disease | >ou= 2 | selim.aractingi@aphp.fr | Cochin |
Contenu d’accordéon
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | 1,2 : First in human | Solid Tumours / NSCLC / Pancreatic Cancer NRG1 Fusion | NRG1 fusion | Critères | 2 | marie.wislez@aphp.fr | Cochin | |
| NCT03157128 | Phase 1/2 Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | 1,2 : First in human | pan-tumoral | Ret-fusion | Critères | locally advanced or metastatic | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT02715284 | Study of TSR-042, an Anti-programmed Cell Death-1 Receptor (PD-1) Monoclonal Antibody, in Participants With Advanced Solid Tumors (GARNET) | 1 | pan-tumoral | – | Critères | recurrent or advanced solid tumor | 2 | jacques.medioni@aphp.fr | HEGP |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | 2 | pan-tumoral (lung & urothelial cancer) | PDL1 expression | Critères | locally advanced or metastatic tumors | 1 | jacques.medioni@aphp.fr | HEGP |
| NCT03899155 | Pan Tumor Nivolumab Rollover Study | 2 | pan-tumoral | – | Critères | – | – | jacques.medioni@aphp.fr | HEGP |
| NCT03692065 | API-CAT STUDY for APIxaban Cancer Associated Thrombosis (API-CAT) | 3 | Cancer-associated Thrombosis – in gastro cancer | – | Critères | tout stade | toute ligne | romain.coriat@aphp.fr | Cochin |
| NCT04282590 | A Study to Investigate the Safety and Efficacy of TRK-750 for the Treatment of Patients With CIPN (Chopin Study) | 2 | Chemotherapy-induced Peripheral Neuropathy – in Gastro cancer | – | Critères | – | 2 | romain.coriat@aphp.fr | Cochin |
| NCT03822117 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207 | 2 | pan-tumoral | FGFR genes mutations/translocation | Critères | advanced or metastatic or is surgically unresectable | 2 | francois.goldwasser@aphp.fr | Cochin |
| NCT02734004 | A Phase I/II Study of MEDI4736 in Combination With Olaparib in Patients With Advanced Solid Tumors. (MEDIOLA) | 1,2 | pan-tumoral (Sein, poumon, ovaire, cancer, gastro) | – | Critères | Advanced | 2 | francois.goldwasser@aphp.fr | Cochin |
| NCT03486873 | Long-term Safety and Efficacy Extension Study for Participants With Advanced Tumors Who Are Currently on Treatment or in Follow-up in a Pembrolizumab (MK-3475) Study | 3 | pan-tumoral | – | Critères | Advanced or Metastatic | 2 | francois.goldwasser@aphp.fr | Cochin |
| NCT03362177 | Study of Romiplostim for Chemotherapy-induced Thrombocytopenia in Adult Subjects With Gastrointestinal, Pancreatic, or Colorectal Cancer | 3 | Chemotherapy-induced Thrombocytopenia | – | Critères | All | – | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03170960 | Study of Cabozantinib in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | 1,2 | pan-tumoral | – | Critères | inoperable, locally advanced, metastatic, or recurrent | 1 ou 2 | jacques.medioni@aphp.fr | HEGP |
| NCT03815643 | Avelumab Program Rollover Study | 3 | pan-tumoral | – | Critères | – | – | jacques.medioni@aphp.fr | HEGP |
PAR
ALTERATION GENETIQUE /
MARQUEUR
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04111705 | Lorlatinib After Failure of First-line Second-generation ALK Kinase Inhibitor in Patients With Advanced ALK-positive Non-small Cell Lung Cancer (ORAKLE) | 2 | Cancer du poumon non à petites cellules (NSCLC) | ALK rearrangement | Critères | locally advanced or metastatic (Stage IIIB or IV ) | 2 | marie.wislez@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04034459 | FOLFOXIRI Plus Cetuximab vs. FOLFOXIRI Plus Bevacizumab 1st-line in BRAF-mutated mCRC | 2 | Cancer du colon | BRAF muté (V600E). RAS wt | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT04526782 | ENCOrafenib With Binimetinib in bRAF NSCLC (ENCO-BRAF) | 2 | Cancer du poumon non à petites cellules (NSCLC) | BRAF | Critères | Stage IV | 2 | marie.wislez@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04348045 | Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02) | 2 | Adénocaecinome du Pancreas | BRCA / KRASS | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique/marqueur | Critères d’inclusion | Stade | ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04154956 | SAR408701 Versus Docetaxel in Previously Treated, Carcinoembryonic Antigen-related Cell Adhesion Molecule 5 (CEACAM5) Positive Metastatic Non-squamous Non-small Cell Lung Cancer Patients (CARMEN-LC03) | 3 | Cancer du poumon non à petites cellules (NSCLC) | CEACAM5 positive | Critères | metastatic | 2 | jacques.medioni@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03829462 | A randomized phase III trial assessing a regorafenib-irinotecan combination (REGIRI) versus regorafenib alone in metastatic colorectal cancer patients after failure of standard therapies, according to the A/A genotype of Cyclin D1 | 3 | Cancer du colon | génotype A/A (rs9344) de la cycline D1 | Critères | Métastatique | ≥2 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04233021 | Study of Osimertinib in Patients With a Lung Cancer With Brain or Leptomeningeal Metastases With EGFR Mutation (ORBITAL) | 2 | Cancer du poumon non à petites cellules (NSCLC) | EGFR | Critères | metastatic (Leptomeningeal & Brain) | 2, 3 or 4 | marie.wislez@aphp.fr | Cochin |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | 2 | Cancer du poumon non à petites cellules (NSCLC) | MET Amplified, EGFR | Critères | Locally advanced or metastatic | 2 | marie.wislez@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03809988 | PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA) | 2 | breast cancer | ER + or/and PgR + & HER2 – | Critères | Advanced | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT03659136 | The XENERA™ 1 Study Tests Xentuzumab in Combination With Everolimus and Exemestane in Women With Hormone Receptor Positive and HER2-negative Breast Cancer That Has Spread | 2 | breast cancer | ER + or/and PgR + & HER2 – | Critères | Locally advanced or metastatic | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT03701334 | A Trial to Evaluate Efficacy and Safety of Ribociclib With Endocrine Therapy as Adjuvant Treatment in Patients With HR+/HER2- Early Breast Cancer (NATALEE) | 3 | Breast cancer | ER + or/and PgR + & HER2 – | Critères | early invasive | 1 | jacques.medioni@aphp.fr | HEGP |
| NCT04478266 | Amcenestrant (SAR439859) Plus Palbociclib as First Line Therapy for Patients With ER (+) HER2(-) Advanced Breast Cancer | 2,3 | Breast Cancer | ER + and HER2 – | Critères | loco-regional recurrent or metastatic | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT04109066 | Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer (CheckMate 7FL) | 3 | Breast cancer | ER + and HER2 – | Critères | Localized invasive | 1 | anne-sophie.bats@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03656536 | A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma | 3 | Cholangiocarcinome | Réarrangement FGFR2 | Critères | LA-Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03390504 | A Study of Erdafitinib Compared With Vinflunine or Docetaxel or Pembrolizumab in Participants With Advanced Urothelial Cancer and Selected Fibroblast Growth Factor Receptor (FGFR) Gene Aberrations | 3 | Urothelial Carcinoma | FGFR | Critères | advanced or metastatic | 2,3 | jacques.medioni@aphp.fr | HEGP |
| NCT04197986 | Study of Oral Infigratinib for the Adjuvant Treatment of Subjects With Invasive Urothelial Carcinoma With Susceptible FGFR3 Genetic Alterations | 3 | Urothelial Carcinoma | FGFR3 | Critères | invasive | adjuvant | jacques.medioni@aphp.fr | HEGP |
| NCT02924376 | Efficacy and Safety of Pemigatinib in Subjects With Advanced/Metastatic or Surgically Unresectable Cholangiocarcinoma Who Failed Previous Therapy – (FIGHT-202) | 2 | Cholangiocarcinoma | FGFR2 | Critères | >ou= 2 | romain.coriat@aphp.fr | Cochin | |
| NCT03773302 | Phase 3 Study of BGJ398 (Oral Infigratinib) in First Line Cholangiocarcinoma With FGFR2 Gene Fusions/Translocations | 3 | Cholangiocarcinoma | FGFR2 fusions/translocations | Critères | unresectable locally advanced or metastatic | 1 | romain.coriat@aphp.fr | Cochin |
| NCT03822117 | Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207 | 2 | pan-tumoral | FGFR genes mutations/translocation | Critères | advanced or metastatic or is surgically unresectable | 2 | francois.goldwasser@aphp.fr | Cochin |
| NCT03745950 | UTOLA: UTerin OLAparib (UTOLA | 2 | Endometrial Cancer | MSI-High, MMR, POLE, FGFR mutations/alterations | Critères | advanced/metastatic | 2 | jerome.alexandre@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03748641 | A Study of Niraparib in Combination With Abiraterone Acetate and Prednisone Versus Abiraterone Acetate and Prednisone for Treatment of Participants With Metastatic Prostate Cancer (MAGNITUDE) | 3 | Castration-Resistant Prostatic Cancer | HRR gene alteration | Critères | metastatic | 1 ou 2 | stephane.oudard@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02260505 | A randomized, multicentre, Phase III trial evaluating the interest of imatinib treatment maintenance or interruption after 3 years of adjuvant treatment in patients with Gastrointestinal Stromal Tumours (GIST) | 3 | GIST | KIT positivity | Critères | Adjuvant | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04348045 | Phase II Study to Evaluate MAintenance Therapy With Olaparib or Selumetinib Plus Durvalumab According to BRCAness and KRAS Somatic Status Personalized in Metastatic Pancreatic Adenocarcinoma Patients (D19-02) | 2 | Adénocaecinome du Pancreas | BRCA / KRAS | Critères | Métastatique | 1 | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04323436 | Study of Capmatinib and Spartalizumab/Placebo in Advanced NSCLC Patients With MET Exon 14 Skipping Mutations | 2 | Cancer du poumon non à petites cellules (NSCLC) | METΔex14 mutation | Critères | locally advanced or metastatic | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03940703 | A Study of Tepotinib Plus Osimertinib in Osimertinib Relapsed MET Amplified NSCLC (INSIGHT 2) | 2 | Cancer du poumon non à petites cellules (NSCLC) | MET Amplified, EGFR | Critères | Locally advanced or metastatic | 2 | marie.wislez@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03186326 | Standard Chemotherapy vs Immunotherapie in 2nd Line Treatment of MSI Colorectal Mestastatic Cancer (SAMCO) | 2 | Cancer du colon | MSI | Critères | Métastatique | 2 | Julien Taieb : jtaieb75@gmail.com et romain.coriat@aphp.fr | HEGP/Cochin |
| NCT04006262 | Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma | 2 | Adénocaecinome oeso-gastrique | dMMR et/ou MSI | Critères | Péri-op | Péri-op | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03745950 | UTOLA: UTerin OLAparib (UTOLA | 2 | Endometrial Cancer | MSI-High, MMR, POLE, FGFR mutations/alterations | Critères | advanced/metastatic | 2 | jerome.alexandre@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04006262 | Peri-operative Association of Immunotherapy (Pre-operative Association of Nivolumab and Ipilimumab, Post-operative Nivolumab Alone) in Localized Microsatellite Instability (MSI) and/or Deficient Mismatch Repair (dMMR) Oeso-gastric Adenocarcinoma | 2 | Adénocaecinome oeso-gastrique | dMMR et/ou MSI | Critères | Péri-op | Péri-op | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT03745950 | UTOLA: UTerin OLAparib (UTOLA | 2 | Endometrial Cancer | MSI-High, MMR, POLE, FGFR mutations/alterations | Critères | advanced/metastatic | 2 | jerome.alexandre@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02912949 | A Study of Zenocutuzumab (MCLA-128) in Patients With Solid Tumors Harboring an NRG1 Fusion | 1,2 : First in human | Solid Tumours / NSCLC / Pancreatic Cancer NRG1 Fusion | NRG1 fusion | Critères | 2 | marie.wislez@aphp.fr | Cochin |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04547504 | PEmbRolizumab verSus chEmotherapy and pEmbrolizumab in Non-small-cell Lung Cancers (NSCLC) With PDL1 ≥ 50 % (PERSEE) | 3 | Cancer du poumon non à petites cellules (NSCLC) | PDL1 (expression >50%) | Critères | Stage IV or . Unresectable and non-eligible to radiotherapy stage III | 1 | marie.wislez@aphp.fr | Cochin |
| NCT03679767 | A Study of INCMGA00012 in Participants With Selected Solid Tumors (POD1UM-203) | 2 | pan-tumoral (lung & urothelial cancer) | PDL1 expression | Critères | locally advanced or metastatic tumors | 1 | jacques.medioni@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT02945033 | Study on Aspirin Versus Placebo in Resected Colon Cancer With PI3K Mutation Stage III or II High Risk (ASPIK French) | 3 | Cancer du colon | PI3K | Critères | Adjuvant/Stage II-III | Adjuvant | Julien Taieb : jtaieb75@gmail.com | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT04194944 | A Study of Selpercatinib (LY3527723) in Participants With Advanced or Metastatic RET Fusion-Positive Non-Small Cell Lung Cancer (LIBRETTO-431) | 3 | Cancer du poumon non à petites cellules (NSCLC) | Ret-fusion | Critères | Advanced or metastatic : Stage IIIB-IIIC or Stage IV | 1 | marie.wislez@aphp.fr / francoise.lepimpec-barthes@aphp.fr | Cochin/HEGP |
| NCT03157128 | Phase 1/2 Study of LOXO-292 in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) | 1,2 : First in human | pan-tumoral | Ret-fusion | Critères | locally advanced or metastatic | 1,2 | jacques.medioni@aphp.fr | HEGP |
| NCT | Titre de l’essai | Phase | Indication | Altération génétique / marqueur | Critères d’inclusion | Stade | Ligne de traitement | Contact | Site d’inclusion |
|---|---|---|---|---|---|---|---|---|---|
| NCT03401788 | A Phase 2 Study of Belzutifan (PT2977, MK-6482) for the Treatment of Von Hippel Lindau (VHL) Disease-Associated Renal Cell Carcinoma (RCC) (MK-6482-004) | 2 | Renal clear cell carcinoma | germline VHL alteration | Critères | localized | 1 | jacques.medioni@aphp.fr | HEGP |
TOUS
LES
ESSAIS
